A team of Australian researchers has developed a new targeted therapeutic approach that could improve treatment for myelofibrosis -- a rare and serious form of blood cancer.

New Delhi, Jan 12 (LatestNewsX) A team of Australian researchers has developed a new targeted therapeutic approach that could improve treatment for myelofibrosis -- a rare and serious form of blood cancer. Myelofibrosis disrupts the body’s ability to produce healthy blood cells, leading to fatigue, pain, enlarged spleen, and reduced quality of life. Although current treatments can help relieve symptoms, there are no treatments to cure the disease.

Circulating inflammatory mediators in the plasma of patients with MF promote the proliferation of megakaryocytes, a new study shows.

Cellenkos recently received Orphan Drug Designation from the FDA for CK0804, a novel therapy aimed at treating myelofibrosis, a rare blood cancer affecting thousands.

AJ1-11095 received orphan drug designation from the FDA in myelofibrosis.

Recent data reveal that Cellenkos' CK0804 therapy significantly reduces spleen volume and transfusion needs in myelofibrosis patients resistant to traditional treatments.

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations